microRNAs: Master regulators as potential therapeutics in cancer - PubMed (original) (raw)
Review
microRNAs: Master regulators as potential therapeutics in cancer
Michela Garofalo et al. Annu Rev Pharmacol Toxicol. 2011.
Abstract
It has been demonstrated that all the known processes involved in cancer, including apoptosis, proliferation, survival, and metastasis, are regulated by small regulatory noncoding RNAs consisting of approximately 19-25 nucleotides; these are named microRNAs (miRNAs). Both loss and gain of miRNA function contribute to cancer development through the upregulation and silencing, respectively, of different target genes. Experimental evidence indicates that the use of miRNA mimics or anti-microRNAs may represent a powerful therapeutic strategy to interfere with key molecular pathways involved in cancer. This review provides insights about how micro- RNAs act as oncogenes and tumor suppressor genes and how these findings, along with our increasing understanding of miRNA regulation, can be applied to optimize recent miRNA-based technologies and make them suitable for clinical applications.
Similar articles
- The therapeutic potential of microRNAs in cancer.
Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S. Thorsen SB, et al. Cancer J. 2012 May-Jun;18(3):275-84. doi: 10.1097/PPO.0b013e318258b5d6. Cancer J. 2012. PMID: 22647365 - MicroRNA-modulated autophagic signaling networks in cancer.
Fu LL, Wen X, Bao JK, Liu B. Fu LL, et al. Int J Biochem Cell Biol. 2012 May;44(5):733-6. doi: 10.1016/j.biocel.2012.02.004. Epub 2012 Feb 10. Int J Biochem Cell Biol. 2012. PMID: 22342941 Review. - MicroRNA expression signatures in solid malignancies.
Galasso M, Sandhu SK, Volinia S. Galasso M, et al. Cancer J. 2012 May-Jun;18(3):238-43. doi: 10.1097/PPO.0b013e318258b5f4. Cancer J. 2012. PMID: 22647360 Review. - MicroRNAs.
Fabbri M, Croce CM, Calin GA. Fabbri M, et al. Cancer J. 2008 Jan-Feb;14(1):1-6. doi: 10.1097/PPO.0b013e318164145e. Cancer J. 2008. PMID: 18303474 Review. - MicroRNAs as therapeutic targets and their potential applications in cancer therapy.
Cho WC. Cho WC. Expert Opin Ther Targets. 2012 Aug;16(8):747-59. doi: 10.1517/14728222.2012.696102. Epub 2012 Jun 13. Expert Opin Ther Targets. 2012. PMID: 22690697 Review.
Cited by
- Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival.
Lee DH, Amanat S, Goff C, Weiss LM, Said JW, Doan NB, Sato-Otsubo A, Ogawa S, Forscher C, Koeffler HP. Lee DH, et al. Oncogenesis. 2013 May 20;2(5):e47. doi: 10.1038/oncsis.2013.10. Oncogenesis. 2013. PMID: 23689287 Free PMC article. - Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells.
Nakano H, Yamada Y, Miyazawa T, Yoshida T. Nakano H, et al. Int J Oncol. 2013 Jun;42(6):1875-82. doi: 10.3892/ijo.2013.1896. Epub 2013 Apr 15. Int J Oncol. 2013. PMID: 23588298 Free PMC article. - miR-22 represses cancer progression by inducing cellular senescence.
Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H. Xu D, et al. J Cell Biol. 2011 Apr 18;193(2):409-24. doi: 10.1083/jcb.201010100. J Cell Biol. 2011. PMID: 21502362 Free PMC article. - miR-25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2.
Lu H, Zhang L, Lu S, Yang D, Ye J, Li M, Hu W. Lu H, et al. Exp Ther Med. 2020 May;19(5):3384-3390. doi: 10.3892/etm.2020.8595. Epub 2020 Mar 11. Exp Ther Med. 2020. PMID: 32266037 Free PMC article. - The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma.
Wang M, Yu F, Chen X, Li P, Wang K. Wang M, et al. Mol Ther Nucleic Acids. 2020 Sep 4;21:13-27. doi: 10.1016/j.omtn.2020.05.011. Epub 2020 May 15. Mol Ther Nucleic Acids. 2020. PMID: 32505000 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources